The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. As in 2022, due to the seasonal impact of managed care reauthorizations in the first quarter of the year, the company expects ORLADEYO net revenue in the first quarter of 2023 to be similar to, or slightly less than, ORLADEYO net revenue in the fourth quarter of 2022. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million. While flat year over year, we expect reductions in R&D spending in 2023 following the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the 10013 clinical program, offset by increases in SG&A to support the U.S. launch and global expansion of ORLADEYO.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Dives after Mixed Earnings
- BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
- BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
- BioCryst reports inducement grants under Nasdaq listing rule